Kite Pharma

EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR KITE‪S KTE-X19 FOR THE TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

— If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis — — Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe —
2400 Broadway Santa Monica, CA 90404

(310) 824-9999